These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
154 related articles for article (PubMed ID: 14499010)
1. Topoisomerase II alpha as a marker predicting the efficacy of anthracyclines in breast cancer: are we at the end of the beginning? Di Leo A; Isola J Clin Breast Cancer; 2003 Aug; 4(3):179-86. PubMed ID: 14499010 [TBL] [Abstract][Full Text] [Related]
2. Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancer. Orlando L; Del Curto B; Gandini S; Ghisini R; Pietri E; Torrisi R; Balduzzi A; Cardillo A; Dellapasqua S; Veronesi P; Viale G; Goldhirsch A; Colleoni M Breast; 2008 Oct; 17(5):506-11. PubMed ID: 18456496 [TBL] [Abstract][Full Text] [Related]
3. Correlation between complete response to anthracycline-based chemotherapy and topoisomerase II-alpha gene amplification and protein overexpression in locally advanced/metastatic breast cancer. Cardoso F; Durbecq V; Larsimont D; Paesmans M; Leroy JY; Rouas G; Sotiriou C; Renard N; Richard V; Piccart MJ; Di Leo A Int J Oncol; 2004 Jan; 24(1):201-9. PubMed ID: 14654958 [TBL] [Abstract][Full Text] [Related]
4. Comparison of topoisomerase-IIalpha gene status between primary breast cancer and corresponding distant metastatic sites. Durbecq V; Di Leo A; Cardoso F; Rouas G; Leroy JY; Piccart M; Larsimont D Breast Cancer Res Treat; 2003 Feb; 77(3):199-204. PubMed ID: 12602919 [TBL] [Abstract][Full Text] [Related]
5. The role of topoisomerase IIα in predicting sensitivity to anthracyclines in breast cancer patients: a meta-analysis of published literatures. Du Y; Zhou Q; Yin W; Zhou L; Di G; Shen Z; Shao Z; Lu J Breast Cancer Res Treat; 2011 Oct; 129(3):839-48. PubMed ID: 21809115 [TBL] [Abstract][Full Text] [Related]
6. Topoisomerase II alpha as a marker predicting anthracyclines' activity in early breast cancer patients: ready for the primetime? Di Leo A; Biganzoli L; Claudino W; Licitra S; Pestrin M; Larsimont D Eur J Cancer; 2008 Dec; 44(18):2791-8. PubMed ID: 18993056 [TBL] [Abstract][Full Text] [Related]
7. HER-2 amplification and topoisomerase IIalpha gene aberrations as predictive markers in node-positive breast cancer patients randomly treated either with an anthracycline-based therapy or with cyclophosphamide, methotrexate, and 5-fluorouracil. Di Leo A; Gancberg D; Larsimont D; Tanner M; Jarvinen T; Rouas G; Dolci S; Leroy JY; Paesmans M; Isola J; Piccart MJ Clin Cancer Res; 2002 May; 8(5):1107-16. PubMed ID: 12006526 [TBL] [Abstract][Full Text] [Related]
8. Topoisomerase II{alpha} amplification does not predict benefit from dose-intense cyclophosphamide, doxorubicin, and fluorouracil therapy in HER2-amplified early breast cancer: results of CALGB 8541/150013. Harris LN; Broadwater G; Abu-Khalaf M; Cowan D; Thor AD; Budman D; Cirrincione CT; Berry DA; Winer EP; Hudis CA; Hayes DF; Friedman P; Ellis M; Dressler L J Clin Oncol; 2009 Jul; 27(21):3430-6. PubMed ID: 19470942 [TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies in male breast cancer: clinical implications of chromosome 17 gene alterations and molecular subtypes. Schildhaus HU; Schroeder L; Merkelbach-Bruse S; Binot E; Büttner R; Kuhn W; Rudlowski C Breast; 2013 Dec; 22(6):1066-71. PubMed ID: 24080492 [TBL] [Abstract][Full Text] [Related]
10. Topoisomerase IIalpha expression rather than gene amplification predicts responsiveness of adjuvant anthracycline-based chemotherapy in women with primary breast cancer. Schindlbeck C; Mayr D; Olivier C; Rack B; Engelstaedter V; Jueckstock J; Jenderek C; Andergassen U; Jeschke U; Friese K J Cancer Res Clin Oncol; 2010 Jul; 136(7):1029-37. PubMed ID: 20052594 [TBL] [Abstract][Full Text] [Related]
11. Topoisomerase II alpha expression and the Ki-67 labeling index correlate with prognostic factors in estrogen receptor-positive and human epidermal growth factor type-2-negative breast cancer. Tokiniwa H; Horiguchi J; Takata D; Kikuchi M; Rokutanda N; Nagaoka R; Sato A; Odawara H; Tozuka K; Oyama T; Takeyoshi I Breast Cancer; 2012 Oct; 19(4):309-14. PubMed ID: 21725655 [TBL] [Abstract][Full Text] [Related]
12. Topoisomerase II-alfa gene as a predictive marker of response to anthracyclines in breast cancer. Almeida D; Gerhard R; Leitão D; Davilla C; Damasceno M; Schmitt F Pathol Res Pract; 2014 Oct; 210(10):675-9. PubMed ID: 25042383 [TBL] [Abstract][Full Text] [Related]
13. Topoisomerase IIalpha gene amplification and response to anthracycline-containing adjuvant chemotherapy in breast cancer. Buzdar AU J Clin Oncol; 2006 Jun; 24(16):2409-11. PubMed ID: 16682721 [No Abstract] [Full Text] [Related]
14. HER2 and TOP2A as predictive markers for anthracycline-containing chemotherapy regimens as adjuvant treatment of breast cancer: a meta-analysis of individual patient data. Di Leo A; Desmedt C; Bartlett JM; Piette F; Ejlertsen B; Pritchard KI; Larsimont D; Poole C; Isola J; Earl H; Mouridsen H; O'Malley FP; Cardoso F; Tanner M; Munro A; Twelves CJ; Sotiriou C; Shepherd L; Cameron D; Piccart MJ; Buyse M; Lancet Oncol; 2011 Nov; 12(12):1134-42. PubMed ID: 21917518 [TBL] [Abstract][Full Text] [Related]
15. Classical lobular breast carcinoma consistently lacks topoisomerase-IIα gene amplification: implications for the tailored use of anthracycline-based chemotherapies. Brunello E; Brunelli M; Manfrin E; Nottegar A; Bersani S; Vergine M; Molino A; Fiorio E; Chilosi M; Gobbo S; Martignoni G; Bonetti F Histopathology; 2012 Feb; 60(3):482-8. PubMed ID: 22168383 [TBL] [Abstract][Full Text] [Related]
16. Topoisomerase II alpha amplification may predict benefit from adjuvant anthracyclines in HER2 positive early breast cancer. Arriola E; Rodriguez-Pinilla SM; Lambros MB; Jones RL; James M; Savage K; Smith IE; Dowsett M; Reis-Filho JS Breast Cancer Res Treat; 2007 Dec; 106(2):181-9. PubMed ID: 17260090 [TBL] [Abstract][Full Text] [Related]
17. Topoisomerase II alpha protein and responsiveness of breast cancer to adjuvant chemotherapy with CEF compared to CMF in the NCIC CTG randomized MA.5 adjuvant trial. O'Malley FP; Chia S; Tu D; Shepherd LE; Levine MN; Huntsman D; Bramwell VH; Andrulis IL; Pritchard KI Breast Cancer Res Treat; 2011 Jul; 128(2):401-9. PubMed ID: 21519837 [TBL] [Abstract][Full Text] [Related]
18. The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patients. Oakman C; Moretti E; Galardi F; Santarpia L; Di Leo A Cancer Treat Rev; 2009 Dec; 35(8):662-7. PubMed ID: 19758759 [TBL] [Abstract][Full Text] [Related]
19. Does topoisomerase II-alpha gene amplification provide useful information for treatment selection in patients with breast carcinoma? Simon R J Clin Oncol; 2011 Jul; 29(21):2941; author reply 2941-4. PubMed ID: 21670460 [No Abstract] [Full Text] [Related]
20. The predictive and prognostic significance of pre- and post-treatment topoisomerase IIα in anthracycline-based neoadjuvant chemotherapy for local advanced breast cancer. Chen S; Huang L; Liu Y; Chen CM; Wu J; Shao ZM Eur J Surg Oncol; 2013 Jun; 39(6):619-26. PubMed ID: 23473851 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]